アキラルアドソルバートからアドソルプション誘発された非対称なアセンブリ
Yuguang Cai1, Steven L Bernasek
1Department of Chemistry, Princeton University, Princeton, New Jersey 08540, USA.
Journal of the American Chemical Society
|October 28, 2004
まとめ
アキラル分子は,グラファイト表面で非対称な構造を形成する. 基板の相互作用によって引き起こされるこの自己組み立てモノレイヤー (SAM) 歪みは,表面科学における新しい発見です.
科学分野:
- 表面科学とは,地表科学である.
- 超分子化学 超分子化学
- マテリアルサイエンス 材料科学
背景:
- 自己組み立てモノレイヤー (SAM) は,表面上の分子組み立てをオーダーしたものです.
- アキラル分子は,吸附時に通常対称な構造を形成します.
- 基板と表面の相互作用は,アドソルバートの形状と対称性に影響を与える可能性があります.
研究 の 目的:
- グラファイト上の1オクターデカノールSAMの対称性破損を調査する.
- 吸附による構造的歪みのメカニズムを理解する.
- アキラルの構成要素から超分子非対称性の形成を調査する.
主な方法:
- 液体/固体界面でスキャニングトンネル顕微鏡 (STM) を利用した.
- 1オクトデカノールの自己組み立て単層構造を高度に秩序付けられた酸化グラフィート (HOPG) に分析した.
- 観察された分子形状と単位細胞の配置.
主要な成果:
- HOPG.の1オクターデカノールSAM構造の対称性破裂が観察されました.
- 格子不一致によるアルカン鎖の非対称的な歪みが実証された.
- 水素結合の要件によって引き起こされる非対称的な歪みを持つシェブロン状のユニットセルを特定しました.
結論:
- この研究は,アキラル表面上のアキラル分子から超分子対称構造を形成する吸附誘発的歪みの最初の例を示しています.
- 観察された非対称性は,アドソルバートの基板に対する反応から生じ,溶液中の分子とは異なる形状につながります.
- この発見は,分子自己組み立てを制御し,アキラル前駆体からキラル構造を作り出すための新しい洞察を提供します.
関連する概念動画
01:29Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:28Drug-Receptor Interaction: Antagonist
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
01:30Combined Effects of Drugs: Antagonism
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...